Wedbush Trims Biogen (NASDAQ:BIIB) Target Price to $213.00
Biogen (NASDAQ:BIIB – Free Report) had its price target decreased by Wedbush from $245.00 to $213.00 in a report released on Wednesday morning, Benzinga reports. Wedbush currently has a neutral rating on the biotechnology company’s stock. Wedbush also issued estimates for Biogen’s Q1 2024 earnings at $3.25 EPS, Q3 2024 earnings at $4.13 EPS, Q4 […]
More Stories
US Land Prices Climb 77 Percent Since Pandemic as Inventory Remains Low: Report
By Mary Prenon Land prices across the United States over the last decade seem to be following the path of...
German Airline Lufthansa to Cut 20,000 Flights to Save Jet Fuel
By Victoria Friedman German airline Lufthansa announced on April 21 that 20,000 short-haul flights would be canceled this summer due...
Duffy Seeking $10 Billion From Congress to Revamp Air Traffic Control System
By Aldgra Fredly U.S. Transportation Secretary Sean Duffy said on April 21 the department requires $10 billion in additional funding...
Iran Attacks 2 Container Ships After Trump Extends Ceasefire
By Tom Ozimek Iranian forces fired on two commercial vessels near the Strait of Hormuz on April 22, UK maritime...
Southern Poverty Law Center Charged With Fraud Over Payments to Informants in Extremist Groups
By Tom Gantert The Southern Poverty Law Center was indicted on federal fraud charges that accused it of illegally raising...
Dr. Oz Says Anti-Fraud Effort Coming to ‘All 50 States’
By Jack Phillips Dr. Mehmet Oz, the administrator of the agency overseeing Medicaid and Medicare, announced Tuesday that his agency’s...